SLC5A2 and type 1 diabetes mellitus: While the majority of RCTs investigating the use of SGLT2-i in T1D revealed higher rates of DKA in the intervention groups, for instance, empagliflozin and dapagliflozin were not significantly associated with a higher DKA risk when data from a meta-analysis were considered [29].